We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Diabetes & Endocrinology

Comparing Calorie-Restricted DASH, Carbohydrate-Restricted, and Low-Purine Diets for Weight Loss and Serum Urate Control in Men with Hyperuricemia

MedXY Editorial Team•Sep 16, 2026•Diabetes & Endocrinology
Dietary patternsgout flarehyperuricemiaSerum Urateweight loss

Highlight

  • Three calorie-restricted diets—DASH, carbohydrate-restricted, and low-purine balanced—produce substantial weight loss in men with overweight or obesity and hyperuricemia.
  • All diets lead to comparable reductions in serum urate levels over 12 weeks, with no statistically significant differences.
  • The DASH diet showed higher dietary adherence and less soft lean mass loss compared to the carbohydrate-restricted diet.
  • Early transient increases in serum urate during week 1 correlate with increased gout flares, underscoring flare-risk management during weight loss initiation.

Study Background

Hyperuricemia, characterized by elevated serum urate (SU) levels, is a critical risk factor for gout and is frequently associated with overweight and obesity. Managing hyperuricemia through lifestyle modifications, including diet, has become a central component of treatment. Although various diet patterns such as the Dietary Approaches to Stop Hypertension (DASH), carbohydrate-restricted, and low-purine diets have been proposed to reduce SU levels and promote weight loss, direct comparisons in controlled trials are limited. Weight loss itself improves urate control, but differential effects of dietary macronutrient composition on serum urate dynamics, body composition, and gout flare incidence in hyperuricemic patients remain inadequately understood.

Study Design

This was a 12-week, open-label, active-comparator randomized trial involving 102 men diagnosed with overweight or obesity (body mass index [BMI] criteria consistent with overweight/obese categories) and hyperuricemia. Participants were randomly assigned in equal proportions (1:1:1) to one of three calorie-restricted dietary interventions:

  • Carbohydrate-Restricted Diet (CRD): Reduced carbohydrate intake within a calorie-restricted framework.
  • DASH Diet: Emphasizes fruits, vegetables, low-fat dairy, and reduced saturated fat, aligned with calorie restriction.
  • Low-Purine Balanced Diet (LPBD): Focused on limiting dietary purines while maintaining calorie restriction.

Each diet prescribed a calorie intake of 20-25 kcal/kg of ideal body weight to promote weight loss. The primary endpoint was the change in serum urate from baseline to week 12. Secondary outcomes included weight loss magnitude, early serum urate dynamics, gout flare occurrence, dietary adherence, and changes in body composition, particularly soft lean mass.

Key Findings

Of the 102 randomized subjects, 85 (83.3%) completed the study. Mean weight loss at 12 weeks was substantial and clinically meaningful across all dietary groups, averaging 8.47 kg (9.3% of baseline weight), with no statistically significant differences between groups (P = 0.99).

Serum urate level decreased in all groups. Adjusted mean SU reductions were:

  • CRD: -0.89 mg/dL
  • DASH: -0.79 mg/dL
  • LPBD: -0.50 mg/dL

No significant difference in SU change between diets was detected (P = 0.48).

An important observation was a transient rise in serum urate during the first week, detected via capillary blood monitoring, which corresponded temporally to an increased incidence of gout flares early in the intervention. This early urate instability suggests that initiating weight loss through dietary modification may temporarily exacerbate gout symptoms.

Dietary adherence was notably higher in the DASH diet group compared to both CRD and LPBD groups. Furthermore, body composition analyses revealed that the DASH diet resulted in less loss of soft lean mass compared to the carbohydrate-restricted diet, implying better preservation of muscle mass during weight reduction.

Expert Commentary

This trial provides valuable head-to-head data on three commonly recommended dietary patterns for men with hyperuricemia and excess weight. The comparable efficacy in serum urate reduction suggests flexibility in dietary choices based on patient preference, metabolic goals, and tolerability.

The higher adherence and preservation of lean mass associated with the DASH diet may confer clinical advantages, as adherence is a major determinant of long-term success and lean mass preservation has implications for metabolic health and physical function.

The early surge in serum urate and coincident gout flares emphasize the need for anticipatory clinical strategies, such as prophylactic anti-inflammatory therapy or tailored monitoring during diet initiation. This phenomenon corroborates earlier evidence linking rapid urate mobilization after weight loss onset to gout flare risk.

Limitations include the open-label design and relatively short duration. Longer-term studies are needed to assess sustainability, long-term urate control, and health outcomes, including cardiovascular and renal effects.

Conclusion

In men with overweight or obesity and hyperuricemia, calorie-restricted DASH, carbohydrate-restricted, and low-purine balanced diets lead to significant weight loss and meaningful reductions in serum urate over 12 weeks without significant differences between them. The DASH diet stands out for better adherence and lean mass preservation.

Clinicians should be aware of early urate fluctuations and risk of gout flares when initiating weight loss diets, advocating appropriate flare-risk management during this period.

This evidence supports patient-centered dietary recommendations permitting flexibility to optimize adherence and metabolic outcomes while managing hyperuricemia and gout risk.

Funding and Trial Registration

The trial was reported by Liu et al. in Diabetes Care (2026); further details regarding funding sources and clinical trial registration were not provided in the original abstract.

References

  • Liu S, Yan L, Huang Y, et al. Calorie-Restricted DASH, Carbohydrate-Restricted, and Low-Purine Diets for Weight Loss and Urate Control in Men With Overweight or Obesity and Hyperuricemia: A Randomized Trial. Diabetes Care. 2026 Sep 15. PMID: 42743064.
  • Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120(5):442-447.
  • Dalbeth N, Merriman TR, Stamp LK. Mechanisms of gout. Lancet. 2016;388(10055):2039-2052.
  • Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336(16):1117-1124.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Evaluating Complication Rates in Post-Weight-Loss Body Contouring: Comparing Surgery, GLP-1 Pharmacotherapy, Combination, and Lifestyle ApproachesThis study investigates postoperative complication rates following body-contouring surgery among patients with differing weight-loss methods, revealing that weight-loss modality does not affect complications, while BMI and diabetes at surgeSep 3, 2026Impact of Weight-Loss Methods on Post-Bariatric Body Contouring Surgery Outcomes: A Comparative AnalysisThis study evaluates complication rates following body contouring after weight loss via bariatric surgery, GLP-1 receptor agonists, combination therapy, and lifestyle changes, finding weight-loss modality does not affect postoperative complSep 1, 2026Association of Adherence to Various Dietary Patterns With Mortality Among Survivors of Myocardial Infarction: An Evidence-Based ReviewPost-MI adherence to diverse healthy dietary patterns is consistently linked to reduced mortality and cardiovascular events, underscoring the importance of diet quality in secondary prevention among MI survivors.Aug 26, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Early Weight Loss in Impaired Glucose Tolerance Significantly Lowers Long-term Cardiovascular and Mortality Risks: Insights from the Da Qing Diabetes Prevention Study
Early weight loss after impaired glucose tolerance diagnosis is linked to markedly reduced long-term risk of cardiovascular events and death, underscoring the importance of early lifestyle interventions in prediabetes management.
Aug 24, 2026
Mazdutide: A Novel Dual Agonist Demonstrates Significant Weight Loss in Adults with Obesity or OverweightMazdutide, a once-weekly glucagon and GLP-1 receptor dual agonist, delivers clinically meaningful weight reduction in adults with obesity or overweight, with higher doses yielding superior outcomes and manageable safety profiles.Aug 22, 2026
Comparative 1-Year Outcomes of Semaglutide, Tirzepatide, and Sleeve Gastrectomy in Obese Adults with Type 2 Diabetes: Insights from Real-World DataA retrospective cohort study evaluating 1-year weight loss, glycaemic control, and safety outcomes among adults with obesity and type 2 diabetes treated with semaglutide, tirzepatide, or sleeve gastrectomy, highlighting higher efficacy withJun 20, 2026